Credit Suisse Group Reiterates “Neutral” Rating for AstraZeneca plc (AZN)

AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by investment analysts at Credit Suisse Group in a research note issued to investors on Monday. They currently have a GBX 4,700 ($60.70) price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would suggest a potential downside of 4.57% from the stock’s previous close.

Several other research firms have also issued reports on AZN. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.32) price objective on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) price objective on AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($77.49) price objective on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Monday, June 5th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 4,963.82 ($64.11).

Shares of AstraZeneca plc (LON:AZN) opened at 4925.00 on Monday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The firm’s market cap is GBX 62.35 billion. The firm has a 50-day moving average price of GBX 4,580.96 and a 200-day moving average price of GBX 4,880.60.

ILLEGAL ACTIVITY WARNING: This story was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://sportsperspectives.com/2017/09/13/credit-suisse-group-reiterates-neutral-rating-for-astrazeneca-plc-azn.html.

In related news, insider Nazneen Rahman bought 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply